Literature DB >> 8899750

Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production.

I Das1, N S Khan, B K Puri, S R Hirsch.   

Abstract

Cellular origins of methylarginines are not precisely known but the presence of free methyl and dimethylarginines in the brain were reported. We have investigated the circulating concentrations of asymmetrical dimethylarginine NG,NG-dimethylarginine (ADMA), NG,NG-dimethylarginine (SDMA), nitrate and nitrite levels in drug naive first episode schizophrenic patients and matched control subjects. Three of those patients were treated with neurolepties for 3 months. Plasma ADMA levels increased significantly but nitrate levels were significantly low compared to control subjects. Drug treatment apparently lowered ADMA levels and increased nitrate levels in plasma. Methylation of arginine to methylarginines may have an important role in regulating signal transduction through the nitric oxide system in the brain, and suggest novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899750     DOI: 10.1016/0304-3940(96)12972-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

1.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.

Authors:  J M Leiper; J Santa Maria; A Chubb; R J MacAllister; I G Charles; G S Whitley; P Vallance
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.

Authors:  Aikaterini Trevlopoulou; Ntilara Touzlatzi; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2015-12-19       Impact factor: 4.530

3.  Nitric oxide stimulates ACTH secretion and the transcription of the genes encoding for NGFI-B, corticotropin-releasing factor, corticotropin-releasing factor receptor type 1, and vasopressin in the hypothalamus of the intact rat.

Authors:  S Lee; C K Kim; C Rivier
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

4.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

5.  Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia.

Authors:  Eiji Suzuki; Toshio Nakaki; Makoto Nakamura; Hitoshi Miyaoka
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

6.  Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study.

Authors:  Anders Jorgensen; Ulla Knorr; Mia Greisen Soendergaard; Jens Lykkesfeldt; Anders Fink-Jensen; Henrik Enghusen Poulsen; Martin Balslev Jorgensen; Niels Vidiendal Olsen; Jonatan Myrup Staalsø
Journal:  BMC Psychiatry       Date:  2015-04-03       Impact factor: 3.630

Review 7.  Toxic Dimethylarginines: Asymmetric  Dimethylarginine (ADMA) and Symmetric  Dimethylarginine (SDMA).

Authors:  You-Lin Tain; Chien-Ning Hsu
Journal:  Toxins (Basel)       Date:  2017-03-06       Impact factor: 4.546

Review 8.  Nitric Oxide Synthase Inhibitors as Antidepressants.

Authors:  Gregers Wegener; Vallo Volke
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-20

9.  Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia.

Authors:  Zhi-Min Yu; Ying Zhao; Jin-Qiong Zhan; Tao Luo; Jian-Wen Xiong; Bin Yu; Bo Wei; Yuan-Jian Yang
Journal:  Front Psychiatry       Date:  2019-01-10       Impact factor: 4.157

Review 10.  The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows.

Authors:  Elli Zoupa; Nikolaos Pitsikas
Journal:  Molecules       Date:  2021-05-26       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.